Key facts
- This page summarizes Renee P. Tannenbaum's Form 4 filing for Cardiff Oncology, Inc. (CRDF).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 01 Jul 2024, 16:09.
Renee P. Tannenbaum - 27 Jun 2024 Form 4 Insider Report for Cardiff Oncology, Inc. (CRDF)
- Reporting relationship
- Director
- Issuer ticker
- CRDF
- Reported as of
- 27 Jun 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 01 Jul 2024, 16:09:21 UTC
- Prior SEC filing
- 23 May 2024
- Next SEC filing
- 16 Dec 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Renee P Tannenbaum
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Renee P. Tannenbaum filed Form 4 for Cardiff Oncology, Inc. (CRDF) on 01 Jul 2024.
Change
- Previous filing in this sequence was filed on 23 May 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
CRDF
transaction
Derivative
Stock Options
Award
- Transaction value
- $0
- Shares
- +29,700
- Change %
- +30%
- Price
- $0.000000
- Shares after
- 128,201
- Date
- 27 Jun 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 29,700
- Exercise price
- $2.33
* marks a reported price that did not pass the local price check.